These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3244183)

  • 41. Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.
    Thomson AB; Keelan M; Lastiwka R; Appelman-Eszczuk S; Zuk L; Drozdowski L; Prentice A; Sinclair P
    Dig Dis Sci; 2003 Oct; 48(10):2045-56. PubMed ID: 14627354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
    Ogawa N
    Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease?
    Hendel J; Hendel L; Aggestrup S
    Aliment Pharmacol Ther; 1995 Dec; 9(6):693-7. PubMed ID: 8824658
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration.
    Hotz J; Kleinert R; Grymbowski T; Hennig U; Schwarz JA
    Aliment Pharmacol Ther; 1992 Feb; 6(1):87-95. PubMed ID: 1543819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ulcer healing: does omeprazole efficacy depend on daytime or 24-hour acid inhibition?
    Savarino V; Mela GS; Zentilin P; Celle G
    Gastroenterology; 1990 Dec; 99(6):1858-60. PubMed ID: 2227311
    [No Abstract]   [Full Text] [Related]  

  • 47. Intravenous omeprazole rapidly raises intragastric pH.
    Walt RP; Reynolds JR; Langman MJ; Smart HL; Kitchingman G; Somerville KW; Hawkey CJ
    Gut; 1985 Sep; 26(9):902-6. PubMed ID: 4029717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A clinical trial of lansoprazole in the treatment of duodenal ulcer].
    Pei Y; Wang B; Chen S
    Zhonghua Nei Ke Za Zhi; 1995 Sep; 34(9):606-8. PubMed ID: 8697927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Importance of adequate acid suppression in the management of Barrett's esophagus.
    Castell DO; Katzka DA
    Gastroenterology; 1999 Dec; 117(6):1509-10. PubMed ID: 10610344
    [No Abstract]   [Full Text] [Related]  

  • 50. Omeprazole and acid peptic disease.
    Piper DW; Yeomans ND; Shearman DJ
    Med J Aust; 1991 Mar; 154(6):374-5. PubMed ID: 2000048
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
    Hirschowitz BI; Simmons J; Mohnen J
    Clin Gastroenterol Hepatol; 2005 Jan; 3(1):39-48. PubMed ID: 15645403
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
    Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
    J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of lansoprazole on intragastric 24-hour pH, meal-stimulated gastric acid secretion, and concentrations of gastrointestinal hormones and enzymes in serum and gastric juice in healthy volunteers.
    Brunner G; Hell M; Hengels KJ; Hennig U; Fuchs W
    Digestion; 1995; 56(2):137-44. PubMed ID: 7750667
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer.
    Savarino V; Mela GS; Zentilin P; Bisso G; Pivari M; Vigneri S; Termini R; Fiorucci S; Usai P; Malesci A; Celle G
    Aliment Pharmacol Ther; 1998 Dec; 12(12):1241-7. PubMed ID: 9882033
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole.
    Londong W; Barth H; Dammann HG; Hengels KJ; Kleinert R; Müller P; Rohde H; Simon B
    Aliment Pharmacol Ther; 1991 Jun; 5(3):245-54. PubMed ID: 1888824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors.
    Hirschowitz BI; Simmons J; Mohnen J
    Aliment Pharmacol Ther; 2002 Feb; 16(2):303-13. PubMed ID: 11860414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effect of a proton pump inhibitor AG-1749 (lansoprazole) on intragastric pH: 24-hour intragastric pH monitoring].
    Kihira K; Yoshida Y; Kasano T; Taniguchi Y; Sato K; Kimura K; Hirose M; Koyama H
    Nihon Shokakibyo Gakkai Zasshi; 1991 Mar; 88(3):672-80. PubMed ID: 1646341
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].
    Kayser S; Flury R; Zbinden R; Fried M; Wirth HP
    Schweiz Med Wochenschr; 1997 Apr; 127(17):722-7. PubMed ID: 9221483
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients.
    Kato M; Asaka M; Kudo M; Sukegawa M; Katagiri M; Koshiyama T; Kagaya H; Nishikawa K; Hokari K; Takeda H; Sugiyama T
    Aliment Pharmacol Ther; 1996 Oct; 10(5):821-7. PubMed ID: 8899093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibitory effects of intravenous lansoprazole on gastric acid hypersecretion in patients with postoperative stress.
    Otani Y; Kitajima M; Sugiyama M; Watanabe Y; Aoki T
    J Clin Gastroenterol; 1995; 20 Suppl 2():S22-6. PubMed ID: 7594333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.